{"entity":{"id":"pasithea-therapeutics","kind":"company","name":"Pasithea Therapeutics","aka":[],"tldr":"Pasithea Therapeutics makes a tablet that blocks MEK, a switch in a growth signalling pathway. It is testing it in people with advanced cancers driven by that pathway and in adults with nerve tumours caused by neurofibromatosis type 1.","summary":"Pasithea Therapeutics Corp., of Miami Beach, Florida, was incorporated in Delaware on 12 May 2020 and listed on the Nasdaq Capital Market (KTTA) after its initial public offering in September 2021, according to its annual report on Form 10-K. It now focuses on RASopathies and MAPK pathway-driven tumours. Its lead candidate PAS-004 is an oral macrocyclic MEK1/2 inhibitor designed for a long half-life. A phase 1 trial (NCT06299839) tests PAS-004 in advanced solid tumours with RAS, NF1 or RAF mutations or after BRAF/MEK inhibitor failure, and a second phase 1 trial (NCT06961565) tests it in adults with NF1-associated plexiform neurofibromas. Its first registered cancer trial, NCT06299839, was posted on ClinicalTrials.gov in March 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://pasithea.com/"},{"label":"SEC filing: Form 10-K for 2025","url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390026036434/0001213900-26-036434-index.htm"},{"label":"ClinicalTrials.gov: phase 1 trial of PAS-004 in advanced solid tumours (NCT06299839)","url":"https://clinicaltrials.gov/study/NCT06299839"},{"label":"ClinicalTrials.gov: phase 1 trial of PAS-004 in NF1 plexiform neurofibromas (NCT06961565)","url":"https://clinicaltrials.gov/study/NCT06961565"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["mek"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Incorporation date, address and ticker are from the Form 10-K filed with the SEC on 30 March 2026, read on 29 October 2026.","Interim PAS-004 data are described by the company as showing favourable pharmacokinetics; the data themselves were not read.","The company earlier ran ketamine clinics; the 10-K reports Pasithea Clinics Inc. dissolved in September 2025."],"hq":"Miami Beach, FL","country":"US","companyType":"biotech","website":"https://pasithea.com/","ticker":"KTTA","founded":2020,"stage":"public","investors":[],"funding":[]},"route":"/companies/pasithea-therapeutics/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/"}]}}